India’s drugmakers noticed wholesome income development throughout all therapies in February as they debuted new medicine and raised costs, an trade report confirmed.
Gross sales within the home pharmaceutical market in February touched ₹18,781 crore, up 7.5% from a yr earlier, knowledge from B2B commerce platform Pharmarack confirmed. Total, the shifting annual complete (MAT) worth development till February was 8.1%, with the trade clocking gross sales of ₹2.24 trillion. MAT refers back to the complete worth of gross sales over the earlier 12 months.
Nonetheless, volumes fell 0.2% in February. “Quantity development general for the market appears to be stagnated,” mentioned Sheetal Sapale, vice-president, business at Pharmarack. That is in step with earlier months, the place market development has been pushed by new introductions and value development, versus quantity development. A number of the months in 2024 noticed volumes decline year-on-year.
Cardiac, gastro lead
Cardiac and gastro remained the highest income contributors, recording virtually 10% worth development in February. Aside from these, urology, blood-related issues and stomatological (mouth/dental-related) therapies additionally registered sturdy double-digit worth development.
Prime contributing therapies like cardiac, gastro, blood-related, hormones, antineoplastics and urology additionally registered sturdy quantity development, together with value rise.
“Sure therapies…among the many prime have proven an excellent unit development as nicely, this could ideally get mirrored within the quantity development proven by these therapies,” Sapale mentioned. These embody cardiac, gastro, gynaecology, anti-diabetes and nutritional vitamins.
Prime gamers see encouraging development
Whereas general income grew 7.5% in February, prime firms comparable to Solar Prescribed drugs, Intas Prescribed drugs, Torrent Prescribed drugs, Zydus Lifesciences and Micro Labs reported double-digit development.
“That is fairly encouraging, for those who have a look at the highest 20 firms, they contribute to virtually 70% of the Indian pharma market…they usually drive the expansion of the market to an important extent,” Sapale mentioned.
GSK’s prescription antibiotic Augmentin retained its spot because the best-selling model within the Indian market in February, adopted by USV’s oral anti-diabetic, Glycomet GP1. Notably, Himalaya’s Liv.52, used for hepatic issues, clinched the third spot for the second consecutive month. Nonetheless, it’s in sixth place if contemplating MAT worth during the last 12 months.
A majority of the highest 20 manufacturers registered promising double-digit development in each worth and items in February. These embody Alkem’s Pan 40 pill, Novo Nordisk and Abbott’s Ryzodeg insulin, Mankind’s manforce pill for erectile dysfunction and Abbott’s thyronorm, used for hypothyroidism.
